USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ANDROBIOSYS, INC.
Address:
875 Ellicott St
BUFFALO, NY 14203-1070
Phone:
N/A
URL:
EIN:
202315778
DUNS:
193493157
Number of Employees:
5
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $417,991.00 3
SBIR Phase II $999,642.00 1
STTR Phase I $96,765.00 1
STTR Phase II $747,553.00 1

Award List:

Circulating Prostate Cancer Progenitor Cell Assay Development

Award Year / Program / Phase:
2008 / STTR / Phase I
Award Amount:
$96,765.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Research Institution:
ROSWELL PARK CANCER INSTITUTE
RI Contact:
Joseph H. Jurkowski
Abstract:
This Phase I contract proposal will evaluate and identify markers associated with prostate cancer progenitor stem cells, that differentiate these cells from adult tissue stem cells and benign prostate progenitor cells. The eventual goal of this work would be to develop a high throughput blood-based… More

PLATELET-BASED NANOPARTICLE THERAPY FOR PROSTATE CANCER

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$149,994.00
Agency:
HHS
Principal Investigator:
Michael Zwick
Abstract:
The goal of this proposal is to develop directed energy transfer methods for imaging, tissue ablation and release of therapeutic modalities targeted to the vasculature of prostate cancer. The platform technology is a freeze-dried human platelet (Stasix par ticles) that contains super paramagnetic… More

Vascular Targeting for Imaging and Treatment of Benign Prostatic Hyperplasia

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$128,052.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Benign Prostatic Hyperplasia/Hypertrophy is a major health problem in the United States, with one-in-three men having urologic problems. Currently available treatment modalities include alpha-blockers that do not affect the underlying pathologic process, and… More

Primary Xenografts of Human Tissue as Surrogates of Cancer In Situ

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$139,945.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): AndroBioSys, Inc. is dedicated to the development of human tissue-based in vivo tools capable of selecting better targeted agents for clinical trials by improved preclinical testing. AndroBioSys has developed the techno logy for reproducible implantation of… More

Platelet-based Nanoparticle Therapy for Prostate Cancer

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$999,642.00
Agency:
HHS
Principal Investigator:
Michael Zwick
Abstract:
The goal of this Phase II proposal is to develop directed energy transfer methods for imaging, tissue ablation and release of therapeutic modalities targeted to the vasculature of prostate cancer. The platform technology is a freeze-dried human platelet (Stasix particles) that contains super… More

Circulating Prostate Cancer Progenitor Cell Assay Development

Award Year / Program / Phase:
2011 / STTR / Phase II
Award Amount:
$747,553.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Michael G. Zwick, CEO – (716) 860-7920
Research Institution:
Roswell Park Cancer Institute
RI Contact:
John T. Blandino
Abstract:
The technical objectives of this Phase II project are to identify unique biomarkers and produce molecular, antibody and peptide reagents that are specific for human prostate cancer progenitor stem cells. We propose to utilize the information from the Phase I award and subsequent research to develop… More